Literature DB >> 6104578

Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.

P A Andrews, D E Brenner, F T Chou, H Kubo, N R Bachur.   

Abstract

Adriamycin and eight metabolites were separated and characterized with an ammonium formate/tetrahydrofuran solvent system on a muBondapak-Phenyl column. Danorubicin and seven daunorubicin metabolites were separated and characterized by the same method. Adriamycin and its major metabolite, adriamycinol, were extracted with 50-70% efficiency from human plasma with chloroform/2-propanol (1:1) and quantified against a daunorubicin internal standard. Urinary concentrations of parent drug, adriamycinol, and the 4-O-sulfate were determined as well. Daunorubicin and daunorubicinol were extracted from human plasma and quantified against an adriamycinol internal standard. The fluorescence detection system has a detection limit of 1.0 pmol, and levels as low as 25 mmol/ml are measurable in plasma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6104578

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  24 in total

1.  Rapid determination of PEGylated liposomal doxorubicin and its major metabolite in human plasma by ultraviolet-visible high-performance liquid chromatography.

Authors:  David L Chin; Bert L Lum; Branimir I Sikic
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2002-11-05       Impact factor: 3.205

2.  Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.

Authors:  S D Averbuch; R E Clawson; N R Bachur; R L Felsted
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport.

Authors:  M Müller; C Meijer; G J Zaman; P Borst; R J Scheper; N H Mulder; E G de Vries; P L Jansen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

4.  A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.

Authors:  W Bolanowska; T Gessner; H Preisler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.

Authors:  D E Brenner; S Galloway; J Cooper; R Noone; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs.

Authors:  A A Gabizon; Y Barenholz; M Bialer
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

Review 7.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

8.  Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.

Authors:  N A Dobbs; C J Twelves; H Gillies; C A James; P G Harper; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).

Authors:  P Dodion; T A Davis; M Rozencweig; N Crespeigne; Y Kenis; N R Bachur
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

10.  Uptake, metabolism, and cytotoxicity of doxorubicin in human Ewing's sarcoma and rhabdomyosarcoma cells.

Authors:  M W DeGregorio; G M Lui; B A Macher; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.